SYK and Alzheimer disease: There are also several oral JAK inhibitors currently in clinical trials for moderate to severe AD in both adults and children, including baricitinib (JAK1/JAK2), upadacitinib (JAK1 inhibitor), Pf-04965842 (JAK1 inhibitor), and ASN002 (JAK, tyrosine kinase 2, spleen tyrosine kinase inhibitor).